Literature DB >> 10588615

Evidence for excessive bronchial inflammation during an acute exacerbation of chronic obstructive pulmonary disease in patients with alpha(1)-antitrypsin deficiency (PiZ).

A T Hill1, E J Campbell, D L Bayley, S L Hill, R A Stockley.   

Abstract

Patients with homozygous (PiZ) alpha(1)-antitrypsin (AAT) deficiency have not only low baseline serum AAT levels (approximately 10 to 15% normal) but also an attenuated acute phase response. They are susceptible to the development of premature emphysema but may also be particularly susceptible to lung damage during bacterial exacerbations when there will be a significant neutrophil influx. The purposes of the present study were to assess the inflammatory nature of acute bacterial exacerbations of chronic obstructive pulmonary disease (COPD) in subjects with AAT deficiency, to compare this with COPD patients without deficiency, and to monitor the inflammatory process and its resolution following appropriate antibacterial therapy. At the start of the exacerbation, patients with AAT deficiency had lower sputum AAT (p < 0.001) and secretory leukoprotease inhibitor (SLPI; p = 0.02) with higher elastase activity (p = 0.02) compared with COPD patients without deficiency. Both groups had a comparable acute phase response as assessed by C-reactive protein (CRP) but the AAT-deficient patients had a minimal rise in serum AAT (to < 6 microM). After treatment with antibiotics, in patients with AAT deficiency, there were significant changes in many sputum proteins including a rise in SLPI levels, and a reduction in myeloperoxidase (MPO) and elastase activity (p < 0. 005 for all measures); the sputum chemoattractants interleukin-8 (IL-8) and leukotriene B(4) (LTB(4)) fell (p < 0.01), and protein leak (sputum/serum albumin ratio) became lower (p < 0.01). The changes were rapid and within 3 d of the commencement of antibiotic therapy the biochemical markers had decreased significantly, but took a variable time thereafter to return to baseline values. In conclusion, patients with AAT deficiency had evidence of increased elastase activity at the start of the exacerbation when compared with nondeficient COPD patients which probably reflects a deficient antiproteinase screen (lower sputum AAT and SLPI). The increased bronchial inflammation at presentation resolved rapidly with 14 d of antibiotic therapy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10588615     DOI: 10.1164/ajrccm.160.6.9904097

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  49 in total

1.  Animal models of emphysema: the next generations.

Authors:  E J Campbell
Journal:  J Clin Invest       Date:  2000-12       Impact factor: 14.808

Review 2.  Alpha-1-antitrypsin deficiency: what next?

Authors:  R A Stockley
Journal:  Thorax       Date:  2000-07       Impact factor: 9.139

Review 3.  Factors influencing airway inflammation in chronic obstructive pulmonary disease.

Authors:  A Hill; S Gompertz; R Stockley
Journal:  Thorax       Date:  2000-11       Impact factor: 9.139

Review 4.  Lung disease associated with alpha1-antitrypsin deficiency.

Authors:  Rubin M Tuder; Sabina M Janciauskiene; Irina Petrache
Journal:  Proc Am Thorac Soc       Date:  2010-11

5.  Acute-phase protein α1-antitrypsin inhibits neutrophil calpain I and induces random migration.

Authors:  Mariam Al-Omari; Elena Korenbaum; Matthias Ballmaier; Ulrich Lehmann; Danny Jonigk; Dietmar J Manstein; Tobias Welte; Ravi Mahadeva; Sabina Janciauskiene
Journal:  Mol Med       Date:  2011-04-11       Impact factor: 6.354

6.  Effect of the leukotriene A4 hydrolase aminopeptidase augmentor 4-methoxydiphenylmethane in a pre-clinical model of pulmonary emphysema.

Authors:  Eliseu O De Oliveira; Kan Wang; Hye-Sik Kong; Suhyon Kim; Matthew Miessau; Robert J Snelgrove; Y Michael Shim; Mikell Paige
Journal:  Bioorg Med Chem Lett       Date:  2011-09-20       Impact factor: 2.823

7.  Role of leukotriene A4 hydrolase aminopeptidase in the pathogenesis of emphysema.

Authors:  Mikell Paige; Kan Wang; Marie Burdick; Sunhye Park; Josiah Cha; Erin Jeffery; Nicholas Sherman; Y Michael Shim
Journal:  J Immunol       Date:  2014-04-25       Impact factor: 5.422

Review 8.  Alpha 1-antitrypsin deficiency. 3: Clinical manifestations and natural history.

Authors:  M Needham; R A Stockley
Journal:  Thorax       Date:  2004-05       Impact factor: 9.139

Review 9.  Role of macrolide therapy in chronic obstructive pulmonary disease.

Authors:  Fernando J Martinez; Jeffrey L Curtis; Richard Albert
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008

10.  Oxidized {alpha}1-antitrypsin stimulates the release of monocyte chemotactic protein-1 from lung epithelial cells: potential role in emphysema.

Authors:  Zhenjun Li; Sam Alam; Jicun Wang; Caroline S Sandstrom; Sabina Janciauskiene; Ravi Mahadeva
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2009-06-12       Impact factor: 5.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.